Pharmaceuticals, Biotechnology and Life Sciences
Sanofi Chief Executive Officer, Olivier Brandicourt, said that the company has started the year with robust growth driven by Specialty Care and Vaccines as well as good performance in Emerging Markets.
Sanofi and Regeneron Pharmaceuticals have resubmitted their Biologics License Application for Kevzara, which is an investigational human monoclonal antibody to be used for treatment of rheumatoid arthritis (RA) with adult patients.
European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Sanofi and Regeneron Pharmaceuticals joint developed product Kevzara (sarilumab), recommending its approval for use in adult patients with moderately to severely active rheumatoid arthritis.
Sanofi has appointed Bill Sibold, a current head of Sanofi Genzyme’s Global Multiple Sclerosis, Oncology and Immunology organization, as Executive Vice President Sanofi Genzyme and member of the Executive Committee, effective July 1, 2017.
JHL Biotech said Wednesday its Clinical Trial Application (CTA) for use of its first product in pipleine, JHL1101 in Phase 1 and Phase 3 clinical trials in Non-Hodgkin’s Lymphoma patients has been accepted by the China Food and Drug Administration (CFDA).
Three of Europe’s top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi <SASY.PA> and Roche <ROG.S> likely to win approvals for two new products, while GlaxoSmithKline <GSK.L> braces for a potential generic rival.
Decision Resources Group (DRG) finds that Nucala’s novel mechanism of action and specific indication for eosinophilic asthma are key drivers behind the agent’s recent success in the severe asthma market.
Ahead of Tuesday’s trading session, Stock-Callers.com puts focus on four major players in the Drug Manufacturers space.
Sanofi’s vaccines global business unit Sanofi Pasteur has signed a deal with AstraZeneca’s biologics bramch MedImmune, to make and sell a monoclonal antibody-called MEDI8897-for the prevention of the most common reason for lower respiratory tract infections in newborns and infants, Respiratory Syncytial Virus (RSV).
Sanofi and Lonza will invest €270 million (CHF 290 million) in a mammalian cell culture site for monoclonal antibody production in Swiss town of Visp, planned for opening in 2020.